Biogen Inc. (BIIB)
| Market Cap | 41.26B |
| Revenue (ttm) | 12.60B |
| Net Income (ttm) | 3.01B |
| Shares Out | 151.90M |
| EPS (ttm) | 19.29 |
| PE Ratio | 14.21 |
| Forward PE | 14.93 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $274.04 |
| Previous Close | $272.11 |
| Change ($) | 1.93 |
| Change (%) | 0.71% |
| Day's Open | 270.66 |
| Day's Range | 270.66 - 279.20 |
| Day's Volume | 936,142 |
| 52-Week Range | 223.25 - 363.92 |
The past six months have seen a huge rotation out of traditional momentum growth stocks to cyclical and value stocks as the bull market ages.
Denali Therapeutics Inc (NASDAQ: DNLI) has announced final results from Phase 1 and Phase 1b studies evaluating BIIB122/DNL151 Parkinson's disease. The drug is being developed in collaboration with Biog...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today released its 2020 Year in Review, which outlines the company's ongoing leadership actions over the past year, includ...
The past six months have seen a huge rotation out of traditional momentum growth stocks to cyclical and value stocks as the bull market ages.
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Biogen Inc (NASDAQ: BIIB) reported a 70.7% fall in Q1 profit as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic drugs. Net income fell to $410.2 millio...
Biogen (BIIB) beats first-quarter estimates for both earnings and sales and ups earnings guidance for 2021.
It's partially because expectations weren't very high in the first place.
The shares of Biogen Inc (NASDAQ:BIIB) were last seen down 3.9% at $259.23, even after the pharmaceutical concern posted first-quarter earnings of $5.34 per share, which topped analysts' estimates.
Biogen Inc. (BIIB) delivered earnings and revenue surprises of 5.53% and 0.39%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Biogen (NASDAQ:BIIB) moved higher by 1.4% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 41.58% year over year to $5.34, which beat...
Biogen Inc reported a 70.7% fall in first-quarter profit on Thursday, as its top-selling multiple sclerosis drug Tecfidera faced increased competition from cheaper generic versions.
Biogen (NASDAQ:BIIB) unveils its next round of earnings this Thursday, April 22. Here is Benzinga's everything-that-matters guide for the earnings announcement.
Investors may want to pay close attention to news coming down the pike soon that could affect the share prices of several pharma companies. The next two months are likely to see a wave of important upda...
Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.
CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from the SPINRAZA® (nusinersen) clinical development program aimed at optimizing outcomes for peo...
CAMBRIDGE, Mass., April 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data from its industry-leading portfolio of multiple sclerosis (MS) therapies to be presented at the A...
CAMBRIDGE, Mass., April 15, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that China's National Medical Products Administration (NMPA) has approved TECFIDERA® (dimethyl fumarate) f...
Biogen Inc. (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., April 14, 2021 (GLOBE NEWSWIRE) -- Biogen (Nasdaq: BIIB) today announced it will host a poster presentation on the design of the EMBARK trial of its Alzheimer's disease investigational...
Sage (SAGE) and partner Biogen (BIIB) announce positive top-line results from the phase II, placebo-controlled KINETIC study in patients with essential tremor.
Sage Therapeutics unveiled promising results for its Biogen-partnered essential tremors treatment known as SAGE-324 on Monday, but Sage stock tripped on worse-than-expected side effects. The post Sage S...
Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have scored their first but narrow win after signing their $3.1 billion deal last year in November. SAGE-324, the second major molecule...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatmen...
Upcoming events could send these stocks screaming higher or lower.
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the nomination of Maria C. Freire, Ph.D. and William D. Jones to stand for election to the company's board...
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
Gilead Sciences, Biogen and Vertex Pharmaceuticals could top expectations in an otherwise soft quarter for biotech stocks, an analyst said Thursday. He sees key products beating forecasts.
Biogen Inc (NASDAQ: BIIB) and Bio-Thera Solutions Ltd have entered into a commercialization and license agreement to develop, manufacture, and commercialize BAT1806, a proposed biosimilar referencing Ge...
CAMBRIDGE, Mass. and GUANGZHOU, China, April 08, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Bio-Thera Solutions, Ltd. (688177.SH) today announced that they entered into a commercialization ...
CAMBRIDGE, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has granted marketing authorization for a subcutaneous (SC) injection of...
Experts worry about how trial data was analyzed.
Biogen Inc.'s (NASDAQ:BIIB) management and shareholders are keeping their fingers crossed that the Food and Drug Administration rules favorably on the company's controversial Alzheimer's drug. The decis...
Mother with ALS seeks life-saving drug from Biogen
CNBC's Meg Tirell joins ‘The News with Shepard Smith' to report on one mother who is seeking help from an experimental drug to treat her terminal illness.
After previously exiting a position in the fourth quarter of 2020, Point72 Asset Management leader Steven Cohen (Trades, Portfolio) disclosed a new 5.03% stake in Tricida Inc. (NASDAQ:TCDA) earlier this...
Biogen's future isn't only wrapped up in Alzheimer's treatment aducanumab, an analyst said Thursday. He identified two low-probability events that could stoke Biogen stock.
Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.
They're making headway into tomorrow's hot markets.
They'll determine short-term and long-term stock performance.
According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned health care stocks have grown their book value per share over the past decade through March 11.
These 4 stocks to buy have good fundamentals, are attractive from a valuation perspective and can provide safety in a volatile 2021. The post 4 Stocks To Buy Ready To Bounce Back From 2020's Dumpster Fi...
A controversial Alzheimer's drug that has weighed on Biogen stock this year could ultimately become a major blockbuster within five years, a market research group predicted Tuesday. The post Why A Contr...
Biogen Inc. (BIIB) reported earnings 30 days ago. What's next for the stock?
Biogen Inc (NASDAQ: BIIB) plans to build a new gene therapy manufacturing facility at its Research Triangle Park manufacturing campuses in North Carolina to support its growing gene therapy pipeline, wi...
CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced its plans to build a new gene therapy manufacturing facility at its Research Triangle Park (RTP) manufactu...
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN ... [Read more...]
| Industry Drug Manufacturers-General | IPO Date Sep 16, 1991 |
| CEO George Scangos | Employees 9,100 |
| Stock Exchange NASDAQ | Ticker Symbol BIIB |
Financial Performance
In 2020, Biogen's revenue was $13.44 billion, a decrease of -6.49% compared to the previous year's $14.38 billion. Earnings were $4.00 billion, a decrease of -32.06%.
Analyst Forecasts
According to 33 analysts, the average rating for Biogen stock is "Hold." The 12-month stock price forecast is 286.97, which is an increase of 4.72% from the latest price.